Tabuk Pharmaceuticals Signs a Commercial Agreement with Renapharma AB
Source: PRNewswire , Author: Posted by BI-ME staff
Posted: Fri March 9, 2018 12:26 pm

JORDAN. -- /PRNewswire/ -- Tabuk Pharmaceuticals Manufacturing Company ("Tabuk"), one of the leading pharmaceutical companies in the Middle East and North Africa region, has entered into an exclusive agreement with Renapharma AB ("Renapharma") on Cholecalciferol Vitamin D3 drop("Detremin").

Renapharma is a leading Swedish company that creates and develops innovative and highly competitive pharmaceutical, nutraceutical and med-tech products.
   
Under this agreement, Renapharma has granted Tabuk exclusive rights to commercialize and distribute Detremin in the Kingdom of Saudi Arabia. Detremin is a highly concentrated non-alcoholic based Vitamin D3 drops.

Detremin is the latest innovation in the field of Vitamin D3 products with many competitive advantages over other formulations, which will increase the treatment compliance.

Dr. Rana Azzam, leading Business Development at Tabuk, said: "This project demonstrates Tabuk's continued commitment to patients and to offering new, innovative medicines within an ongoing collaboration with global partners to deliver on its mission to help improve the lives of patients".

"This exclusive distribution agreement allows Renapharma to access critically important markets and meet a major objective of expanding our global reach. Tabuk Pharmaceuticals is one of the leading pharmaceutical companies in the MENA region which makes them an ideal partner to develop and commercialize Detremin in the region. We look forward to a long a successful cooperation with Tabuk", commented Ms. Caroline Danielson, CEO of Renapharma.

Photo Captions:
1. (above)  Tabuk Pharmaceuticals logo (PRNewsfoto/Tabuk Pharmaceuticals)
2. (inset)     For illustrative purposes only (File photo)

 

MIDDLE EAST BUSINESS COMMENT & ANALYSIS

date:Posted: June 18, 2018
UAE. 24% of Middle Eastern entrepreneurs are motivated by social impact and view it as their top priority as a business owner; 66% are undertaking angel investing.
date:Posted: June 16, 2018
UAE. MENA region recorded 93 deals amounting to US$15.4b in Q1 2018; UAE records highest announced Q1 deal value in the region at US$5.1b; Oil & gas deal value reached US$7.2b in Q1 2018; Almost 80% of MENA boards focused on portfolio transformation.
date:Posted: June 14, 2018
UAE. McAfee report sounds industry alarm: Don't start the blockchain revolution without making security a top priority.
dhgate